Informação sobre produto
Nome:
Fidaxomicin Dimethoxy Impurity
Sinónimos:
- (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dimethoxybenzoyl)-2-O-methyl-beta-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-beta-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one
- 3''',5'''-Di-O-methyltiacumicin B
Descrição:
Applications 3’’’,5’’’-Dideshydroxy-3’’’,5’’’-dimethoxy Fidaxomicin is a derivative of Fidaxomicin (F335400), a nonabsorbed macrocyclic antibiotic, and is also the first antimicrobial to be approved by the FDA for the treatment of Clostridium difficile infection (CDI) in 20 years.
References Babakhani, F., et al.: Clin. Infect. Dis., 55, S162 (2012); Venugopal, A., et al.: Clin. Infect. Dis., 54, 568 (2012)
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
TRC
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
1086.09
Fórmula:
C54H78Cl2O18
Cor/forma:
White to Off-White Solid
InChI:
InChI=1S/C54H78Cl2O18/c1-15-32-24-28(6)35(58)20-18-17-19-33(25-68-53-47(67-14)42(61)44(31(9)69-53)71-51(64)37-34(16-2)38(55)46(66-13)39(56)45(37)65-12)50(63)70-36(30(8)57)22-21-27(5)23-29(7)43(32)72-52-41(60)40(59)48(54(10,11)74-52)73-49(62)26(3)4/h17-19,21,23-24,26,30-32,35-36,40-44,47-48,52-53,57-61H,15-16,20,22,25H2,1-14H3/b18-17-,27-21+,28-24+,29-23-,33-19+/t30-,31-,32+,35-,36+,40-,41+,42+,43+,44-,47+,48+,52?,53-/m1/s1
Chave InChI:
InChIKey=VSQXOITUBILBJL-RTZOBUOVSA-N
SMILES:
CCc1c(Cl)c(OC)c(Cl)c(OC)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C/C=C\C[C@@H](O)/C(C)=C\[C@H](CC)[C@@H](OC3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C\C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
